The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine
BACKGROUND: Microseminoprotein-beta (MSMB) regulates apoptosis and using genome-wide association studies the rs10993994 single nucleotide polymorphism in the MSMB promoter has been linked to an increased risk of developing prostate cancer. The promoter location of the risk allele, and its ability to...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2010
|
| _version_ | 1826293476520624128 |
|---|---|
| author | Whitaker, H Kote-Jarai, Z Ross-Adams, H Warren, A Burge, J George, A Bancroft, E Jhavar, S Leongamornlert, D Tymrakiewicz, M Saunders, E Page, E Mitra, A Mitchell, G Lindeman, G Evans, D Blanco, I Mercer, C Rubinstein, W Clowes, V Douglas, F Hodgson, S Walker, L Donaldson, A Izatt, L Dorkins, H Male, A Tucker, K Stapleton, A Lam, J Kirk, J Lilja, H Easton, D Cooper, C Eeles, R Neal, D |
| author_facet | Whitaker, H Kote-Jarai, Z Ross-Adams, H Warren, A Burge, J George, A Bancroft, E Jhavar, S Leongamornlert, D Tymrakiewicz, M Saunders, E Page, E Mitra, A Mitchell, G Lindeman, G Evans, D Blanco, I Mercer, C Rubinstein, W Clowes, V Douglas, F Hodgson, S Walker, L Donaldson, A Izatt, L Dorkins, H Male, A Tucker, K Stapleton, A Lam, J Kirk, J Lilja, H Easton, D Cooper, C Eeles, R Neal, D |
| author_sort | Whitaker, H |
| collection | OXFORD |
| description | BACKGROUND: Microseminoprotein-beta (MSMB) regulates apoptosis and using genome-wide association studies the rs10993994 single nucleotide polymorphism in the MSMB promoter has been linked to an increased risk of developing prostate cancer. The promoter location of the risk allele, and its ability to reduce promoter activity, suggested that the rs10993994 risk allele could result in lowered MSMB in benign tissue leading to increased prostate cancer risk. METHODOLOGY/PRINCIPAL FINDINGS: MSMB expression in benign and malignant prostate tissue was examined using immunohistochemistry and compared with the rs10993994 genotype. Urinary MSMB concentrations were determined by ELISA and correlated with urinary PSA, the presence or absence of cancer, rs10993994 genotype and age of onset. MSMB levels in prostate tissue and urine were greatly reduced with tumourigenesis. Urinary MSMB was better than urinary PSA at differentiating men with prostate cancer at all Gleason grades. The high risk allele was associated with heterogeneity of MSMB staining and loss of MSMB in both tissue and urine in benign prostate. CONCLUSIONS: These data show that some high risk alleles discovered using genome-wide association studies produce phenotypic effects with potential clinical utility. We provide the first link between a low penetrance polymorphism for prostate cancer and a potential test in human tissue and bodily fluids. There is potential to develop tissue and urinary MSMB for a biomarker of prostate cancer risk, diagnosis and disease monitoring. |
| first_indexed | 2024-03-07T03:30:41Z |
| format | Journal article |
| id | oxford-uuid:ba9cdf50-8d91-4afb-82f6-d0981c621127 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:30:41Z |
| publishDate | 2010 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:ba9cdf50-8d91-4afb-82f6-d0981c6211272022-03-27T05:11:09ZThe rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urineJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ba9cdf50-8d91-4afb-82f6-d0981c621127EnglishSymplectic Elements at OxfordPublic Library of Science2010Whitaker, HKote-Jarai, ZRoss-Adams, HWarren, ABurge, JGeorge, ABancroft, EJhavar, SLeongamornlert, DTymrakiewicz, MSaunders, EPage, EMitra, AMitchell, GLindeman, GEvans, DBlanco, IMercer, CRubinstein, WClowes, VDouglas, FHodgson, SWalker, LDonaldson, AIzatt, LDorkins, HMale, ATucker, KStapleton, ALam, JKirk, JLilja, HEaston, DCooper, CEeles, RNeal, DBACKGROUND: Microseminoprotein-beta (MSMB) regulates apoptosis and using genome-wide association studies the rs10993994 single nucleotide polymorphism in the MSMB promoter has been linked to an increased risk of developing prostate cancer. The promoter location of the risk allele, and its ability to reduce promoter activity, suggested that the rs10993994 risk allele could result in lowered MSMB in benign tissue leading to increased prostate cancer risk. METHODOLOGY/PRINCIPAL FINDINGS: MSMB expression in benign and malignant prostate tissue was examined using immunohistochemistry and compared with the rs10993994 genotype. Urinary MSMB concentrations were determined by ELISA and correlated with urinary PSA, the presence or absence of cancer, rs10993994 genotype and age of onset. MSMB levels in prostate tissue and urine were greatly reduced with tumourigenesis. Urinary MSMB was better than urinary PSA at differentiating men with prostate cancer at all Gleason grades. The high risk allele was associated with heterogeneity of MSMB staining and loss of MSMB in both tissue and urine in benign prostate. CONCLUSIONS: These data show that some high risk alleles discovered using genome-wide association studies produce phenotypic effects with potential clinical utility. We provide the first link between a low penetrance polymorphism for prostate cancer and a potential test in human tissue and bodily fluids. There is potential to develop tissue and urinary MSMB for a biomarker of prostate cancer risk, diagnosis and disease monitoring. |
| spellingShingle | Whitaker, H Kote-Jarai, Z Ross-Adams, H Warren, A Burge, J George, A Bancroft, E Jhavar, S Leongamornlert, D Tymrakiewicz, M Saunders, E Page, E Mitra, A Mitchell, G Lindeman, G Evans, D Blanco, I Mercer, C Rubinstein, W Clowes, V Douglas, F Hodgson, S Walker, L Donaldson, A Izatt, L Dorkins, H Male, A Tucker, K Stapleton, A Lam, J Kirk, J Lilja, H Easton, D Cooper, C Eeles, R Neal, D The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine |
| title | The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine |
| title_full | The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine |
| title_fullStr | The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine |
| title_full_unstemmed | The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine |
| title_short | The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine |
| title_sort | rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein beta expression in tissue and urine |
| work_keys_str_mv | AT whitakerh thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT kotejaraiz thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT rossadamsh thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT warrena thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT burgej thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT georgea thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT bancrofte thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT jhavars thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT leongamornlertd thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT tymrakiewiczm thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT saunderse thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT pagee thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT mitraa thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT mitchellg thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT lindemang thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT evansd thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT blancoi thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT mercerc thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT rubinsteinw thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT clowesv thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT douglasf thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT hodgsons thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT walkerl thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT donaldsona thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT izattl thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT dorkinsh thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT malea thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT tuckerk thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT stapletona thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT lamj thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT kirkj thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT liljah thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT eastond thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT cooperc thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT eelesr thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT neald thers10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT whitakerh rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT kotejaraiz rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT rossadamsh rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT warrena rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT burgej rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT georgea rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT bancrofte rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT jhavars rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT leongamornlertd rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT tymrakiewiczm rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT saunderse rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT pagee rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT mitraa rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT mitchellg rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT lindemang rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT evansd rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT blancoi rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT mercerc rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT rubinsteinw rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT clowesv rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT douglasf rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT hodgsons rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT walkerl rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT donaldsona rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT izattl rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT dorkinsh rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT malea rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT tuckerk rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT stapletona rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT lamj rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT kirkj rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT liljah rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT eastond rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT cooperc rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT eelesr rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine AT neald rs10993994riskalleleforprostatecancerresultsinclinicallyrelevantchangesinmicroseminoproteinbetaexpressionintissueandurine |